Eli Lilly shares hit record high after retatrutide data

Shares of Eli Lilly reached record highs on Monday, June 8, 2026, following the release of new clinical data for its next-generation obesity drug, retatrutide. The data, presented over the weekend at the American Diabetes Association's Scientific Sessions in New Orleans, reinforced investor confidence in the company's expanding pipeline and its competitive position in the lucrative weight-loss market.

The stock climbed approximately 4% in early trading, significantly outperforming rival Novo Nordisk, whose shares declined despite announcing its oral Wegovy therapy had surpassed 3 million prescriptions since its January launch. The market reaction highlighted the intensifying competition between the two pharmaceutical leaders.

The latest results from Phase 3 trials showed retatrutide, a weekly injection, delivered substantial benefits beyond weight loss. In adults with obesity, the drug reduced moderate-to-severe obstructive sleep apnea severity by 60.6% and cut knee osteoarthritis pain by up to 73.1%. These findings build on earlier data showing patients with obesity lost an average of 28% of their body weight over 80 weeks on the highest dose. For patients with type 2 diabetes,...